104 related articles for article (PubMed ID: 1304801)
21. [In vitro and in vivo effects of ginsenoside Rh2 on the proliferation of serous cystadenocarcinoma of the human ovary].
Tode T; Kikuchi Y; Sasa H; Hirata J; Kita T; Imaizumi E; Nagata I
Nihon Sanka Fujinka Gakkai Zasshi; 1992 May; 44(5):589-94. PubMed ID: 1619319
[TBL] [Abstract][Full Text] [Related]
22. [Enhanced sensitivity of ovarian cell line to cisplatin induced by mifepristone and its mechanism].
Qin TN; Wang LL
Di Yi Jun Yi Da Xue Xue Bao; 2002 Apr; 22(4):344-6. PubMed ID: 12390742
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression.
Jain D; Patel N; Shelton M; Basu A; Roque R; Siede W
Cancer Chemother Pharmacol; 2010 Oct; 66(5):945-52. PubMed ID: 20101404
[TBL] [Abstract][Full Text] [Related]
25. Direct cloning of human ovarian carcinoma cells in agar.
Hamburger AW; Salmon SE; Kim MB; Trent JM; Soehnlen BJ; Alberts DS; Schmidt HJ
Cancer Res; 1978 Oct; 38(10):3438-44. PubMed ID: 210939
[No Abstract] [Full Text] [Related]
26. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
[TBL] [Abstract][Full Text] [Related]
27. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray.
Sakamoto M; Kondo A; Kawasaki K; Goto T; Sakamoto H; Miyake K; Koyamatsu Y; Akiya T; Iwabuchi H; Muroya T; Ochiai K; Tanaka T; Kikuchi Y; Tenjin Y
Hum Cell; 2001 Dec; 14(4):305-15. PubMed ID: 11925933
[TBL] [Abstract][Full Text] [Related]
28. Establishment and characterization of three new cell lines derived from the ascites of human ovarian carcinomas.
Alama A; Barbieri F; Favre A; Cagnoli M; Noviello E; Pedullà F; Viale M; Foglia G; Ragni N
Gynecol Oncol; 1996 Jul; 62(1):82-8. PubMed ID: 8690298
[TBL] [Abstract][Full Text] [Related]
29. cis-Diamminedichloroplatinum-resistant cell lines derived from human epithelial ovarian carcinoma express increased susceptibility to angiogenesis inhibitor TNP-470.
Tamura M; Takakuwa K; Tanaka K
Gynecol Oncol; 2004 Feb; 92(2):530-6. PubMed ID: 14766244
[TBL] [Abstract][Full Text] [Related]
30. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
31. Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin.
Solár P; Horváth V; Kleban J; Koval' J; Solárová Z; Kozubík A; Fedorocko P
Neoplasma; 2007; 54(2):127-30. PubMed ID: 17319785
[TBL] [Abstract][Full Text] [Related]
32. Spermidine/spermine N1-acetyltranferase modulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistant human ovarian cancer cell lines.
Marverti G; Ligabue A; Guerrieri D; Paglietti G; Piras S; Costi MP; Farina D; Frassineti C; Monti MG; Moruzzi MS
Gynecol Oncol; 2010 May; 117(2):202-10. PubMed ID: 20031193
[TBL] [Abstract][Full Text] [Related]
33. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
34. Cytokinetic and morphologic differences in ovarian cancer cells treated with ET-18-OCH3 and the DNA-interacting agent, etoposide.
Fujiwara K; Koike H; Ohishi Y; Shirafuji H; Kohno I; Modest EJ; Kataoka S
Anticancer Res; 1997; 17(3C):2159-67. PubMed ID: 9216681
[TBL] [Abstract][Full Text] [Related]
35. [Gene expression profiling of human ovarian epithelial tumors by digo nucleotide microarray].
Konno R
Hum Cell; 2001 Dec; 14(4):261-6. PubMed ID: 11925926
[TBL] [Abstract][Full Text] [Related]
36. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
[TBL] [Abstract][Full Text] [Related]
37. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.
Parker RJ; Vionnet JA; Bostick-Bruton F; Reed E
Cancer Res; 1993 Jan; 53(2):242-7. PubMed ID: 8417816
[TBL] [Abstract][Full Text] [Related]
38. [Isolation of cisplatin-resistant subline from human ovarian cancer cell line and analysis of its cell-biological characteristics].
Yoshiya N; Adachi S; Misawa Y; Yuzawa H; Honda T; Kanazawa K; Takeuchi S Tanaka K; Tanaka K
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):7-14. PubMed ID: 2647872
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.
Kotoh S; Naito S; Yokomizo A; Kumazawa J; Asakuno K; Kohno K; Kuwano M
Cancer Res; 1994 Jun; 54(12):3248-52. PubMed ID: 8205547
[TBL] [Abstract][Full Text] [Related]
40. [Effects of combination chemotherapy of ovarian cancer in vitro].
Lu SM
Zhonghua Yi Xue Za Zhi; 1992 Oct; 72(10):590-2, 638. PubMed ID: 1284340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
